Patents by Inventor Philip J. Burck

Philip J. Burck has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds and methods for treatment of thromboembolic disorders using an adduct of t-PA
    Patent number: 5272076
    Abstract: The present invention provides adducts of human t-PA derivatives, which comprise a t-PA derivative that lacks the Finger, Growth Factor and Kringle 1 domains, bound to an amphipathic molecule. The invention also provides methods for preparing the adducts and compositions for the treatment of thromboembolic disorders.
    Type: Grant
    Filed: June 13, 1991
    Date of Patent: December 21, 1993
    Assignee: Eli Lilly and Company
    Inventors: Philip J. Burck, Ronald E. Zimmerman
  • Method of treating thromboembolic disorders by administration of diglycosylated t-PA variants
    Patent number: 5242688
    Abstract: The present invention provides a method of treating thromboembolic disorders with the diglycosylated form of a tissue plasminogen activator derivative that lacks the Finger, EGF and Kringle I domains of the native tissue plasminogen activator molecule.
    Type: Grant
    Filed: December 24, 1990
    Date of Patent: September 7, 1993
    Assignee: Eli Lilly and Company
    Inventors: Philip J. Burck, Charles V. Jackson, Gerald F. Smith
  • Contraceptive methods
    Patent number: 4493699
    Abstract: Long chain alkyl and alkenyl sulfonates, sulfates and sulfoalkyl alkanoate salts, administered intravaginally for contraception.
    Type: Grant
    Filed: April 8, 1982
    Date of Patent: January 15, 1985
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Zimmerman, Philip J. Burck, C. David Jones, Arvind L. Thakkar
  • Contraceptive device
    Patent number: 4469671
    Abstract: A contraceptive device for intravaginal use comprising a bioinsoluble, biocompatible polyurethane and an acrosin inhibitor.
    Type: Grant
    Filed: February 22, 1983
    Date of Patent: September 4, 1984
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Zimmerman, Philip J. Burck, Richard L. Dunn
  • Contraceptive methods and compositions
    Patent number: 4264575
    Abstract: Introduction of a pharmaceutically acceptable non-toxic cation salt of a straight-chain or branched chain alkyl sulfonate having from 11 to 16 carbon atoms into the uterine lumen or vaginal cavity prevents conception. Sodium tetradecyl sulfonate is preferred.
    Type: Grant
    Filed: April 8, 1980
    Date of Patent: April 28, 1981
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Zimmerman, Philip J. Burck, C. David Jones, Arvind L. Thakkar
  • Contraceptive methods and compositions
    Patent number: 4264576
    Abstract: Introduction of a pharmaceutically acceptable non-toxic cation salt of a sulfoalkyl alkanoate, for example, sodium sulfopropyl dodecanoate, into the uterine lumen or vaginal cavity prevents conception.
    Type: Grant
    Filed: April 8, 1980
    Date of Patent: April 28, 1981
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Zimmerman, Philip J. Burck, C. David Jones, Arvind L. Thakkar
  • Contraceptive methods and compositions
    Patent number: 4264577
    Abstract: Introduction of a compound of the formula:R--OSO.sub.3 --Mwherein R is:(a) C.sub.11 -C.sub.30 straight chain alkyl or alkenyl;(b) C.sub.10 -C.sub.30 branched chain alkyl or alkenyl, the .alpha.-carbon of which is not branched; or(c) C.sub.13 -C.sub.30 branched chain alkyl or alkenyl, the .alpha.-carbon of which is branched,and M is a pharmaceutically acceptable non-toxic cation; into the uterine lumen or vaginal cavity prevents conception. Sodium n-tetradecyl sulfate is preferred.
    Type: Grant
    Filed: April 8, 1980
    Date of Patent: April 28, 1981
    Assignee: Eli Lilly and Company
    Inventors: Ronald E. Zimmerman, Philip J. Burck, C. David Jones, Arvind L. Thakkar
  • Contraceptive methods and compositions
    Patent number: 4264578
    Abstract: Introduction of a pharmaceutically acceptable non-toxic cation salt of a sterol sulfate into the uterine lumen or vaginal cavity prevents conception. Potassium or pyridinium .beta.-sitosteryl sulfate is preferred.
    Type: Grant
    Filed: April 8, 1980
    Date of Patent: April 28, 1981
    Assignee: Eli Lilly and Company
    Inventors: Philip J. Burck, Ronald E. Zimmerman, Arvind L. Thakkar